Published in Cancer Weekly, January 18th, 2005
The researchers also determined that CA 125 is not a sensitive tool for ovarian cancer screening.
T. Bjorge and colleagues, Norwegian Radium Hospital, Oslo, set out "to find the frequency of the most common BRCA1 mutations in women with ovarian tumors identified from a population-based cancer registry and in the general population, to estimate the relative risk of ovarian tumors among the mutation carriers, and to explore the value of using CA 125 as a prediagnostic...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.